Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations

v3.10.0.1
Condensed Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenue - related party $ 0 $ 0 $ 50 $ 0
Operating expenses:        
Research and development 5,316 2,188 13,165 5,388
Research and development – licenses acquired 1,000 300 1,075 2,375
General and administrative 1,340 4,596 5,133 8,293
Total operating expenses 7,656 7,084 19,373 16,056
Loss from operations (7,656) (7,084) (19,323) (16,056)
Interest income 138 144 431 369
Net Loss $ (7,518) $ (6,940) $ (18,892) $ (15,687)
Net loss per common share outstanding, basic and diluted $ (0.28) $ (0.27) $ (0.70) $ (0.63)
Weighted average number of common shares outstanding, basic and diluted 27,146,721 26,186,924 26,871,505 24,936,626